Record Display for the EPA National Library Catalog
RECORD NUMBER: 402 OF 1720Main Title | Evaluation of the Potential Carcinogenicity of Daunomycin (20830-81-3). | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
CORP Author | Syracuse Research Corp., NY. ;Environmental Monitoring and Services, Inc., Washington, DC.;Environmental Protection Agency, Washington, DC. Office of Health and Environmental Assessment. | |||||||||||
Publisher | Jun 88 | |||||||||||
Year Published | 1988 | |||||||||||
Report Number | EPA-68-03-3112 ;EPA-68-03-3182; EPA/600/8-91/098 ; OHEA-C-073-072 | |||||||||||
Stock Number | PB93-185197 | |||||||||||
Additional Subjects | Toxicity ; Risk assessment ; Public health ; Exposure ; Neoplasms ; Hazardous materials ; Tolerances(Physiology) ; Daunomycin ; Daunorubicin ; Carcinogenicity ; Dose-response relationships ; CAS Registry No: 20830-81-3 | |||||||||||
Holdings |
|
|||||||||||
Collation | 17p | |||||||||||
Abstract | Daunomycin is a probable human carcinogen, classified as weight-of-evidence Group B2 under the EPA Guidelines for Carcinogen Risk Assessment. Evidence on potential carcinogenicity from animal studies is 'Sufficient', and the evidence from human studies is 'No Data'. Data available are inadequate for calculating a potency factor (F) and no quantitative inferences can be made. Daunomycin is, therefore, assigned to the median potency factor range and placed in potency group 2 according to the CAG's methodology for evaluating potential carcinogens. Combining the weight-of-evidence group and the potency group, daunomycin is assigned a 'MEDIUM' hazard ranking for the purposes of RQ adjustment. |